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Abstract
Background: Gene targeted therapy refers to any therapy focused on one of the many biological
features of the tumor. Such features are mediated by specific genes that are involved in tumor
metastasis, recurrence, poor response to chemotherapy and others. Hypoxia is an important
pathognomonic feature of many malignant tumors including SCLC (small cell lung cancer). HIF-
1alpha, which is induced by hypoxia, is the most important regulatory factor of many specific genes
that can influence the biological features of tumors.
Methods: In this study, we tried to elucidate the changes in gene expression profiles of SCLC NCI-
H446 cells mediated by HIF-1alpha. According to different treatments of cells, three experimental
pairwise comparisons were designed: hypoxia group vs. control group, Ad5-HIF-1alpha group vs.
Ad5 group, and Ad5-siHIF-1 alpha group Vs Ad5 group.
Results: Results from the analysis of gene expression profiles indicated that there were 65 genes
upregulated and 28 genes downregulated more than two-fold in all three experimental pairwise
comparisons. These genes were involved in transport, signal-transduction, cell adhesion/motility,
growth factor/cytokines, transcription, inflammatory response, metabolic process, in addition to
others. SOCS1, IGFBP5, IL-6 and STAT3 were also upregulated at protein level. SOCS1 could
significantly induce apoptosis and suppress growth of NCI-H446 cells but HIF-1alpha could induce
growth and suppress apoptosis.
Conclusions:  Through this research, we are trying to find novel functional genes that are
mediated by HIF-1alpha and provide the theoretical basis for new therapeutic targets. HIF-1 alpha
maybe upregulate the expression of SOCS1 through mediation of STAT3 and IL-6. In addition,
SOCS1 could significantly induce apoptosis and suppress growth of NCI-H446 cells. This was
contrary to HIF-1alpha and it indicated that there might be an antagonism effect between HIF-
1alpha and SOCS1 on regulating growth and apoptosis of NCI-H446 cells.
Background
Lung cancers used to be categorized into small cell lung
cancer (SCLC) and non-small cell lung cancer (NSCLC).
About 13%-15% of all lung cancers worldwide are SCLC.
As a type of malignant tumor, SCLC shows many general
clinical manifestations such as early metastasis, frequent
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recurrence and tendency toward poor response to chemo-
therapy. Some authors [1,2] have previously demon-
strated that these clinical manifestations are partially the
result of a series of biological changes that occurred in
tumor cells when responding to hypoxia. In other words,
the hypoxic microenvironment promotes the malignant
development of the tumor. In this biochemical process,
the hypoxia-inducible factor-1alpha subunits (HIF-
1alpha) play an important role. Expression of HIF-1alpha
has been confirmed to be unregulated in hypoxic condi-
tions and degraded in normoxic conditions [3,4].
Changes in gene expression directly or indirectly induced
by HIF-1alpha have extended to over 100 genes to date.
Through mediating the expression of some relevant func-
tional genes, HIF-1alpha influences the pathways of met-
abolic adaptation, erythropoiesis, angiogenesis and
vascular tone, cell growth and differentiation, survival and
apoptosis, and is therefore a critical factor in many biolog-
ical features of the majority of solid tumors [5], including
SCLC. It has been verified that multiple genes and their
functions are involved in the occurrence and development
of SCLC [6]. However, one question that remains to be
answered is how the hypoxic microenvironment changes
the gene expression profile of SCLC cells by the regula-
tional activation of HIF-1alpha. To imitate the hypoxic
microenvironment of the tumor in vivo, we cultured
SCLC NCI-H446 cells in a hypoxic incubator. Addition-
ally, we modified SCLC NCI-H446 cells with Ad5-HIF-
1alpha (an adenovirus encoding a active form of HIF-
1alpha that is resistant to O2-dependent degradation) and
incubated these cells in a normoxic incubator. In order to
further clarify the effect on the gene expression profile of
NCI-H446 cells by HIF-1alpha, we blocked the expression
of HIF-1alpha using Ad5-siHIF-1alpha transfection. For
these studies, microarray technology was used, which pro-
vides a unique opportunity to study the global gene
expression profile by providing a molecular portrait of cel-
lular events in a single experiment [7]. In our study, the
Human Genome U133A Array approach was utilized to
evaluate the changes of the gene expression profile in
NCI-H446 cells after culturing in a hypoxic environment
and transfection with Ad5-HIF-1alpha or Ad5-siHIF-
1alpha. We applied this approach to analyze the differen-
tial expression of functional genes. Our investigation tried
to identify more novel functional genes that respond to
the HIF-1 alpha changes mediated by hypoxia and hoped
to provide the theoretical basis for gene targeted therapy
in SCLC. In addition, we found that SOCS1 (which can
negatively regulate growth factor signaling and affect the
process of proliferation and apoptosis) was upregulated
by HIF-1alpha. There may be an antagonism effect
between HIF-1alpha and SOCS1 on inducing growth or
suppressing apoptosis of NCI-H446 cells. In our study, we
carried out research to address this point.
Materials and methods
Cell culture
The NCI-H446 cell line was obtained from the American
Type Culture Collection (CAS Shanghai Institutes for Bio-
logical Sciences cell bank) and cultured in RPMI-1640
medium (Sigma-Aldrich Co, St. Louis, MO, USA) supple-
mented with 10% fetal bovine serum (FBS, Hyclone) and
100 μg/ml kanamycin at 37°C in humidified atmosphere
containing 5% CO2 and 20% O2. The medium was rou-
tinely changed 2-3 d after seeding. All experiments were
performed using exponentially growing cells and repeated
at least 3 times.
Adenoviral construction and cell transfection
We used Ad5 (full name: tumor-specific replication-defec-
tive adenovirus type 5) as the vector. Ad5- HIF-1alpha,
Ad5-siHIF-1alpha, Ad5-SOCS1 and Ad5-siSOCS1 were
constructed and gifted from the Viral-Gene Therapy
department of Shanghai Eastern Hepatobiliary Surgery
Hospital. The cells in the microarray analysis were divided
into five groups: control group (cells cultured in a nor-
moxic environment with 20% O2), hypoxia group (cells
cultured under a hypoxic environment with 1% O2), Ad5
group (cells transfected with Ad5), Ad5-HIF-1alpha group
(cells transfected with Ad5-HIF-1alpha) and Ad5-siHIF-
1alpha group (cells transfected with Ad5-siHIF-1alpha
and cultured under hypoxic environment with 1% O2).
For transfection, cells were cultured in 6-well plates and
exposed to viral supernatant in the absence of cytokines
and serum with different multiplicities of infection
(MOIs): the number of plaque-forming units (pfu) per
cell. The efficiency of transfection was estimated by deter-
mining the percentage of enhanced green fluorescence
protein (EGFP)-positive cells in cells infected with Ad5-
EGFP. To establish optimal conditions for NCI-H446 cells
by adenoviral gene transfer, different titers of Ad5-EGFP
were used. After transfection for 3 days, half of the virus-
containing medium was replaced for the first time, and
then plates were further incubated and all the medium
was changed every 2 days. According to a report by Meng
Jiang [8], we imitated the hypoxic microenvironment in
vivo by putting the cells into a hypoxic chamber with an
auto purge airlock (Thermo Forma, Tri-tube, USA). Envi-
ronmental hypoxic conditions were established in an air-
tight humidified chamber that was continuously flushed
with a gas mixture containing 1% O2, 5% CO2 and 94%
N2 at 37°C.
RNA extraction, Microarray hybridization and data 
analysis
All the cells were washed gently with ice-cold phosphate-
buffered saline (PBS) and lysed with 3 ml Trizol (Invitro-
gen, San Diego, CA, USA). According to the manufac-
turer's protocol, total RNA was extracted and purified with
the RNAeasy kit (Qiagen, USA). The concentration of totalJournal of Experimental & Clinical Cancer Research 2009, 28:150 http://www.jeccr.com/content/28/1/150
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RNA was measured by a Biophotometer (Eppendorf, Ger-
many), and the quality of purified RNA was confirmed by
agarose gel electrophoresis using ethidium bromide stain-
ing. cDNA was synthesized from each RNA sample using
SuperScript System (Invitrogen) as a template for the
preparation of biotin-labeled cRNA according to the
GeneChip IVT Labeling Kit. The hybridization fluid was
prepared and Biotin-labeled cRNA was hybridized to the
GeneChip Human Genome U133 Plus 2.0, washed,
stained with phycoerythrin-streptavidin and scanned
according to the manufacturer's protocol. The microarray
contained 54,614 human gene probe sets, each of which
consisted of 11 probe pairs corresponding to a single
mRNA transcript. After being saved as raw image files, all
the data were converted into probe sets and analyzed by
the GCOS software based on the method of normaliza-
tion. Annotation by Unigene database http://
www.ncbi.nlm.nih.gov/entrez/query.fcgi?db_unigene,
gene number, gene symbol, and gene description were
carried out using the database http://
david.abcc.ncifcrf.gov/summary.jsp and Affymetrix data-
bases. The results are presented as the ratios of the hypoxia
group vs. control (normoxia) group, Ad5-HIF-1alpha
group vs. Ad5 group1 and Ad5-si HIF-1alpha group vs.
Ad5 group2. Ratio values with an increase or decrease of
more than 2 folds were defined as differential expression.
The primary data sets are all available at http://www.hop
kins-genomics.org/expression.html.
Selecting genes for real-time quantitative PCR
The microarray data were verified by real-time quantita-
tive PCR. Six upregulated genes were selected to validate
and PCR primer pairs were as follows:
human IGFBP5: sense 5'-TGCCCAGAAAATGAAA
AAGG-3'and
antisense 5'-GGATGACACAGCGTGAGAGA -3'
human IRS4: sense 5'-TACGGCAATGGCTTTATCAC-
3' and
antisense 5'-CCCTCCTGCAACTTCTCAAT-3'
human TNFAIP6: sense 5'-TTTCAAGGGTGCCAGTT-
TCG-3' and
antisense 5'-GGGAGGCCAGCATCGTGTA-3'
human SOCS1: sense 5'-TAGCACACAACCAGGT-
GGCA-3'and
antisense 5'-GCTCTGCTGCTGTGGAGACTG-3'
human IL-6: sense 5'-CGGGAACGAAAGAGAAGCT
CTA-3' and
antisense 5'- CGCTTGTGGAGAAGGAGTTCA-3'
human VEGF-A: sense 5'- CCATGAACTTTCTGCT-
GTCTT-3' and
antisense 5'-TCGATCGTTCTGTATCAGTCT-3'
Five downregulated genes were selected to validate and
PCR primer pairs were as follows:
Human IGFBP3: sense 5'-GACGTATCTAGCAGCT-
GTCT-3'and
antisense 5'- CGAGGTCTCATGATCTCTCT -3'
Human ZNF569: sense 5'-GGAAAGAAACGACT-
GGGAGC-3' and
antisense 5'-CGACTAGACGCTATTGTGATT-3'
Human SOCS-2: sense 5'-CCTTTATCTGACCAAAC-
CGCTCTA-3'and
antisense 5'-TGTTAATGGTGAGCCTACAGAGA T
G -3' 
Human SIRPa: sense 5'-GGCGGGTGAGGAGGAGCT-
GCAGGTGAT-3' and
antisense 5'-GCGGGCTGCGGGCTGGTCTGAA
TG-3'
Human XRCC4: sense 5'-AAGATGTCTCATTCAGAC
TTG-3'and
antisense 5'-CCGCTTATAAAGATCAGTCTC-3'
Real-time PCR was performed using SYBR ExScript RT-
PCR Kit according to the manufacturer's protocol (Takara
Biotechnology (Dalian) Co. Ltd., Dalian, China) and
using the iCycler Real-Time PCR Detection System (Bio-
Rad). All the RNA samples, which were chosen from the
microarray samples, were run in duplicate on 96-well
optical PCR plates. The thermal cycling conditions were as
follows: 1 cycle of 95.0°C for 10 min; 40 cycles of 95.0°C
for 5 s; 60.0°C for 30 s; and 81 cycles of 55.0°C for 10
min (with an increase set point temperature after cycle 2
by 0.5°C). GAPDH was used as an internal control. The
primers used for SYBR Green real-time PCR were designed
according to the NCBI website http://
www.ncbi.nlm.nih.gov and were synthesized by Shanghai
Sangon Biological Engineering Technology & Services Co.,
Ltd. The relative changes in gene expression were calcu-
lated using the equation: relative changes in gene expres-
sion = 2-ΔΔCT where ΔCt = Cttarget- CtGAPDH and ΔΔCt =Journal of Experimental & Clinical Cancer Research 2009, 28:150 http://www.jeccr.com/content/28/1/150
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ΔCtAd5-HIF-1alpha-ΔCtAd5,  ΔΔCt = ΔCtAd5-ΔCtAd5-siHIF-1a  or
ΔΔCt = ΔCtHypoxia-ΔCtnormoxia
Western blot analysis
The cells of each group were washed with mild PBS to
remove the remaining medium, and cellular proteins were
extracted by disrupting cells in RIPA lysis buffer (Beyotime
Institute of Biotechnology): 50 mM Tris pH 7.4, 1 mM
EDTA, 250 mM NaCl, 0.1% NP40, 1% Triton X100, 0.5%
SDS, 0.25% DOC, 1 mM NaF, 5 mM NaVO3, 1 mg/ml
aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, and 1
mM PMSF. The protein was electrophoresed on 12% SDS-
polyacrylamide gels and transferred to a PVDF membrane.
The membranes were then blocked at room temperature
for 1 h with 5% non-fat milk in Tris buffered saline con-
taining Tween20 (TBST). The rabbit anti-human primary
antibodies (Wuhan Boster Biological Engineering Tech-
nology Limited Company) that detect IGFBP5, SOCS1, IL-
6 and STAT3(Signal Transducer and Activator of Tran-
scription 3)were incubated with membranes overnight at
4°C. The membranes were subsequently incubated with
goat anti-rabbit peroxidase-conjugated secondary anti-
bodies, and immunoreactivity was detected by using an
enhanced Chemiluminescence kit and captured on X-ray
film. β-actin was used as an internal control.
Analysis of the effect on cell growth and apoptosis by 
HIF-1alpha and SOCS1
In this study, all cells were divided into 7 groups: Ad5
group - transfection with Ad5 (control group); Ad5-HIF-
1a group - transfection with Ad5-HIF-1 alpha; Ad5-si HIF-
1alpha group - transfection with Ad5-siHIF-1alpha; Ad5-
SOCS1 group - transfection with Ad5-SOCS1; Ad5-
siSOCS1 group - transfection with Ad5-siSOCS1; Ad5-
HIF-1alpha/siSOCS1 group - co-transfection with Ad5-
HIF-1alpha and Ad5- siSOCS1; Ad5-siHIF-1alpha/SOCS1
group - co-transfection with Ad5-siHIF-1 alpha and Ad5-
SOCS1; Ad5-HIF-1alpha/SOCS1 group - co-transfection
with Ad5-HIF-1 alpha and Ad5-SOCS1. NCI-H446 cells of
each group were prepared as a cell suspension and plated
at a density of 1 × 104 cells/well into 6-well plates. Every
24 h, 3 wells were trypsinized for cell counting and repeat-
edly counted for 7 d to draw the growth curve. Then, cells
of each group were washed with PBS and fixed in 70%
ethanol for 24 h at 4°C. The fixed cells were resuspended
in PBS. After incubation for 10 min, the apoptotic rates
were analyzed by terminal transferase dUTP nick-end
labeling (tunel stain)and all the procedures were per-
formed according to tunel kit's protocol(Beyotime Insti-
tute of Biotechnology). After DAB coloration we began to
calculate the apoptosis rate by using the formula: apopto-
sis rate = number of tunel positive cells/number of total
cells.
Statistical analysis
All experiments were carried out in triplicate. Student's t
test or ANOVA was used to compare parameters between
the different study groups. A P value of less than 0.05 was
considered statistically significant. The statistical analyses
were performed with the Windows SPSS 13.0 package.
Results
Transfection efficiency and expression of HIF-1alpha
After adenoviral construction was completed, they were
used to infect NCI-H446 cells. Using fluorescent micros-
copy, we observed that the transfection efficiency of the
adenoviral vectors into cells was high and reached more
than 95% at an MOI of 50. We selected this group to
detect the mRNA expression of HIF-1alpha at different
stages by real-time quantitative PCR. The primer pairs
were: human HIF-1alpha: sense 5'-CAT CAG CTA TTT
GCG TGT GAG GA-3' and antisense 5'-AGC AAT TCA TCT
GTG CTT TCA TGT C-3'. Results show that 60 h after trans-
fection, the expression of HIF-1alpha mRNA reach the
highest level in the Ad5- HIF-1alpha group and the lowest
level in the Ad5-siHIF-1alpha group. Therefore, for the
following studies human NCI-H446 cells were transduced
with Ad5, Ad5- HIF-1alpha or Ad-siHIF-1alpha for 60 h at
an MOI of 50.
Microarray analysis of the gene expression profile of 
human small cell lung cancer NCI-H446 cells in response 
to hypoxia by HIF-1alpha
To evaluate the effect of HIF-1alpha on gene expression
profiles, cells from all 5 groups were harvested for isola-
tion of total RNA, which was used to synthesize cDNA and
labeled cRNA for hybridization to microarrays containing
54,614 gene probes. The experimental protocol was inde-
pendently performed 3 times. We used the comparative
analysis algorithm provided by Genespring to compare
differences between the hypoxia group and control group,
Ad5-HIF-1alpha group and Ad5 group, Ad5-siHIF-1alpha
group and Ad5 group. The genes regulated by HIF-1alpha
were determined using a 2.0-fold change cutoff value
because this cutoff captured many, but not all of the genes
that were previously identified as target genes of HIF-
1alpha. We identified 65 gene probes with increased
expression (more than 2.0-fold) in the hypoxia and Ad5-
HIF-1alpha groups but decreased expression (more than
2.0-fold) in the Ad5-siHIF-1alpha group; 28 gene probes
were identified with decreased expression (more than 2.0-
fold) in the hypoxia and Ad5-HIF-1alpha groups but
increased expression (more than 2.0-fold) in the Ad5-
siHIF-1alpha group (Figure 1B). As supplements for the
above-mentioned analysis, we performed scatter-graphs
of gene chip scanning signals (Figure 1A) and the cluster-
ing analysis of gene expression (Figure 1C) to describe the
differential expression in response to HIF-1alpha.Journal of Experimental & Clinical Cancer Research 2009, 28:150 http://www.jeccr.com/content/28/1/150
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Major functional categories of upregulated genes in 
response to hypoxia by HIF-1alpha
Analysis of genes that were upregulated revealed several
large categories of gene products associated with immune
response, transport, signal transduction, cell adhesion/
motility, growth factor/cytokines, transcription, inflam-
matory response, metabolic process, apoptosis and others
(Table 1). The gene most highly upregulated by HIF-
1alpha was CLIC2. The largest groups upregulated by HIF-
1alpha in NCI-H446 cell were genes associated with trans-
port and the metabolic process. Among the genes associ-
ated with transport, the largest category was the SLC
(solute carrier) gene family including SLC6A2, SLC9A2,
SLC38A6, SLC16A6, SLC41A2, SLC12A8, SLC12A6,
SLC39A8 and SLCO4A1. The genes of the SLC family such
as SLC2A14 and SLC2A3 and the AKR1 (aldo-keto reduct-
ase 1) family such as AKR1C1, AKR1C2, AKR1C3 and
AKR1B10 were associated with the metabolic processes of
tumor cells. Ten genes were identified that encode
cytokines and growth factors including the known target
genes of HIF-1alpha such as VEGF, IGFBP5, PDGFC and
CRLF1. Novel upregulated genes that might be implicated
as target genes of HIF-1alpha including TNFAIP6,
HMOX1, HMGA2, HEY1, PLA2G4A and SOCS1. Another
large category of target genes encoded transcription fac-
tors; among these CREM and ZNF277 were target genes of
HIF-1alpha. Among the genes encoding inflammatory
response factors, 8 genes (TNFAIP6, IL1R1, BDKRB1,
C4A, PTGS2, TNFRSF11B, FN1 and IL6) were upregu-
lated. No gene encoding for inflammatory response fac-
tors were downregulated by HIF-1alpha. To validate the
microarray data, aliquots from the same RNA prepara-
tions were analyzed by quantitative real-time PCR for six
genes: IGFBP5, IRS4, TNFAIP6, SOCS1, IL-6, VEGF-A. The
results of the real-time PCR showed a similar trend of reg-
ulation as the microarray data despite the different upreg-
ulational fold (Figure 2A).
Major functional categories of downregulated genes in 
response to hypoxia by HIF-1alpha
Among the 28 genes that showed more than 2.0-fold
decreased expression, were genes in pathways such as pro-
tein amino acid phosphorylation, growth factors/
cytokines, cell adhesion/motility, transcription, transport
and others(Table 2). Just like the categories of genes
upregulated by HIF-1alpha, the largest category of genes
that were downregulated were genes that encode transport
factors (including two members of SLC gene family:
SLC16A14 and SLC35F3). The genes encoding growth fac-
tors/cytokines included SOCS2 and IGFBP3, which are in
the same gene families with SOCS1 and IGFBP5, respec-
tively. The expression of IGFBP3, ZNF569, SOCS2, SIRPa
and XRCC4 genes were analyzed by real-time PCR to val-
idate. The results also showed a similar trend of regulation
as the microarray data (Figure 2B).
Effects of HIF-1alpha and hypoxia on SOCS1, IGFBP5, IL-
6 and STAT3 protein expression in NCI-H446 cells
It is well known that regulation at the mRNA level does
not always predict regulation at the protein level. Hence,
we investigated the changes in the expression levels of
SOCS1 and IGFBP5 proteins by Western blot analysis.
SOCS1 and IGFBP5, which were upregulated by HIF-
1alpha at the mRNA level, are closely related with biolog-
Microarray and data analysis (A) Scatter graph of gene chip scanning signals: Scatter plot of the normalized microarray datasets  resulting from analysis of human SCLC NCI-H446 cells Figure 1
Microarray and data analysis (A) Scatter graph of gene chip scanning signals: Scatter plot of the normalized 
microarray datasets resulting from analysis of human SCLC NCI-H446 cells. All 54,614 gene probes are repre-
sented in this plot. (B) Experimental design and summary of results: Text in red indicates the total number of genes upregu-
lated in 3 experimental conditions (Ad5-HIF-1alpha vs. Ad5; Ad5 vs. Ad5-siHIF-1alpha; hypoxia vs. control-normoxia). Text in 
blue indicates the total number of genes downregulated in 3 experimental conditions (same as above). Finally, 65 genes were 
upregulated and 28 genes were downregulated in all 3 pairwise comparisons. (C) Hierarchical clustering analysis of gene 
expression profiles of three pairwise comparisons (Ad5-siHIF-1alpha group vs. Ad5 group1, Ad5-HIF-1alpha group vs. Ad5 
group2, hypoxia group vs. normoxia group). The normalization of all the data of genes with differential expression was handled 
by clustering analysis using software Gene Spring 7.0. The graph of clustering analysis on the right side is the magnification 
about the local region (as marked by black border) of the total clustering analysis.Journal of Experimental & Clinical Cancer Research 2009, 28:150 http://www.jeccr.com/content/28/1/150
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Table 1: 65 genes upregulated by HIF-1alpha more than 2.0-fold in three pairwise comparisons
UniGeneID Gene name Gene Symbol Fold change(ratio ≥ 2)
Ad5-HIF-1alpha/
Ad5
Ad5-siHIF-1alpha/
Ad5
Hypoxia/
normoxia
Immune response
Hs.351812 C-type lectin domain family 4, member C CLEC4C 12.99 -9.66 17.54
Hs.190622 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58
DDX58 5.28 -3.12 4.77
Hs.163173 interferon induced with helicase C 
domain 1
IFIH1 3.73 -2.07 4.15
Hs.529053 complement component 3 C3 2.29 -2.10 3.17
Transport
Hs.655445 chloride intracellular channel 2 CLIC2 12.12 -3.92 10.46
Hs.257352 apolipoprotein L, 6 APOL6 8.57 -3.98 7.92
Hs.78036 solute carrier family 6, member 2
(neurotransmitter transporter, 
noradrenalin)
SLC6A2 5.28 -4.01 4.79
Hs.250083 solute carrier family 9, member 2
(sodium/hydrogen exchanger)
SLC9A2 2.64 -2.19 3.17
Hs.200738 solute carrier family 38, member 6 SLC38A6 2.46 -2.94 2.86
Hs.42645 solute carrier family 16, member 6
(monocarboxylic acid transporter 7)
SLC16A6 2.30 -3.16 4.90
Hs.577463 solute carrier family 41, member 2 SLC41A2 2.32 -4.23 5.19
Hs.658514 solute carrier family 12, member 8
(potassium/chloride transporters)
SLC12A8 2.14 -3.01 3.75
Hs.510939 solute carrier family 12, member 6 SLC12A6 2.12 -2.01 3.41
Hs.288034 solute carrier family 39, member 8
(zinc transporter)
SLC39A8 2.05 -2.92 4.35
Hs.235782 solute carrier organic anion transporter
family member 4A1
SLCO4A1 2.05 -2.88 5.12
Signal transduction
Hs.592215 insulin receptor substrate 4 IRS4 6.96 -5.79 5.13
Hs.20961 G protein-coupled estrogen receptor 1 GPER1 6.50 -3.05 7.99
Hs.75199 protein phosphatase 2, regulatory 
subunit B
beta isoform
PPP2R5B 3.48 -2.51 6.70
Hs.145404 phosphatidylinositol-specific 
phospholipase C
X domain containing 3
PLCXD3 3.40 -4.91 3.46
Hs.497402 leucine-rich repeat-containing G protein-
coupled receptor 6
LGR6 2.46 -2.19 4.10
Hs.458414 interferon induced transmembrane 
protein 1
IFITM1 2.29 -3.43 2.86
Hs.645475 amphiregulin 
(schwannoma-derived growth factor)
AREG 2.05 -3.07 3.86
Cell adhesion/motility
Hs.143250 tenascin C (hexabrachion) TNC 5.28 -3.23 6.44
Hs.2375 egf-like module containing, mucin-like, 
hormone receptor-like 1
EMR1 3.48 -3.31 4.57
Hs.415762 lymphocyte antigen 6 complex, locus D LY6D 2.30 -4.30 3.61
Hs.479439 protocadherin 7 PCDH7 2.00 -3.29 2.70
Hs.2962 S100 calcium binding protein P S100P 4.59 -2.16 4.32
Hs.332012 immunoglobulin superfamily, member 8 IGSF8 2.00 -2.47 2.85
Growth factors/cytokines
Hs.73793 Vascular endothelial growth factor-A VEGF-A 6.76 -3.98 15.40
Hs.437322 tumor necrosis factor, alpha-induced 
protein 6
TNFAIP6 6.96 -4.75 12.17
Hs.635441 insulin-like growth factor binding 
protein 5
IGFBP5 4.83 -4.45 9.80
Hs.517581 heme oxygenase (decycling) 1 HMOX1 2.64 -2.73 4.58Journal of Experimental & Clinical Cancer Research 2009, 28:150 http://www.jeccr.com/content/28/1/150
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ical properties of tumor (as we will describe in the discus-
sion). Result of the Western blot analysis (Figure 3A, B, C)
showed that the protein levels of SOCS1 and IGFBP5 were
significantly upregulated after transfection with HIF-
1alpha or after culturing cells in the hypoxic environment
but were significantly downregulated after transfection
with siHIF-1alpha. Besides two factors above-mentioned,
inflammatory factor IL-6 and downstream signal trans-
ducer STAT3 were also upregulated at the protein level in
Ad5-HIF-1alpha group and hypoxia group especially in
hypoxia group but downregulated in Ad5-siHIF-1alpha
group (Figure 3D, E, F).
Effect on cell growth and apoptosis by HIF-1alpha and 
SOCS1
Transfection with Ad5-HIF-1alpha increased the growth
rate of NCI-H446 cells, and the growth rate of NCI-H446
cells decreased after transfection with Ad5-si HIF-1alpha;
however, the effects of SOCS1 were the opposite (Figure
4A, B). The growth curve of the co-transfection group (Fig-
ure 4C, D) confirmed the above-mentioned result. In
Ad5-HIF-1alpha/SOCS1 group we could see that in expo-
nential phase (from 5-8 days) the growth rate of cells also
decreased comparing to Ad5-HIF-1alpha group (Figure
4E). In the assay of tunel stain the apoptotic cells were
Hs.505924 high mobility group AT-hook 2 HMGA2 2.63 -2.83 2.09
Hs.234434 hairy/enhancer-of-split related with 
YRPW motif1
HEY1 2.60 -2.15 3.89
Hs.570855 platelet derived growth factor C PDGFC 2.26 -3.21 4.37
Hs.497200 phospholipase A2, group IVA PLA2G4A 2.14 -2.55 6.67
Hs.114948 cytokine receptor-like factor 1 CRLF1 2.00 -3.05 4.75
Hs.50640 suppressor of cytokine signaling 1 SOCS1 7.46 -7.13 8.06
Transcription
Hs.501778 tripartite motif-containing 22 TRIM22 4.56 -4.14 4.47
Hs.1706 interferon regulatory factor 9 IRF9 3.73 -2.16 3.90
Hs.567641 myocardin MYOCD 3.03 -2.08 3.58
Hs.655904 zinc finger protein 277 ZNF277 2.13 -2.74 2.37
Hs.200250 cAMP responsive element modulator CREM 2.05 -2.31 3.45
Inflammatory response
Hs.437322 tumor necrosis factor, alpha-induced 
protein 6
TNFAIP6 6.97 -6.07 7.39
Hs.701982 interleukin 1 receptor, type I IL1R1 2.64 -2.21 4.00
Hs.525572 bradykinin receptor B1 BDKRB1 2.48 -2.51 2.99
Hs.534847 complement component 4A (Rodgers 
blood group)
C4A 2.16 -2.03 2.66
Hs.196384 prostaglandin-endoperoxide synthase 2 PTGS2 2.07 -2.96 3.05
Hs.81791 tumor necrosis factor receptor 
superfamily member 11b
TNFRSF11B 2.00 -2.77 3.65
Hs.203717 fibronectin 1 FN1 2.31 -2.57 3.84
Hs.654458 interleukin 6 (interferon, beta 2) IL6 5.29 -2.27 6.10
Metabolic process
Hs.387367 cytochrome P450, family 39, subfamily A, 
polypeptide 1
CYP39A1 11.32 -7.58 12.30
Hs.460260 aldo-keto reductase family 1, member C1 AKR1C1 9.85 -3.45 8.47
Hs.567256 aldo-keto reductase family 1, member C2 AKR1C2 3.10 -2.37 2.90
Hs.116724 aldo-keto reductase family 1, member B10 AKR1B10 3.03 -2.10 2.83
Hs.78183 aldo-keto reductase family 1, member C3 AKR1C3 2.65 -2.07 2.30
Hs.419240 solute carrier family 2, member 1 SLC2A14 2.60 -2.91 3.22
Hs.419240 solute carrier family 2, member 3 SLC2A3 2.46 -2.17 3.91
Hs.572518 UDP-glucose dehydrogenase UGDH 2.00 -2.77 3.14
Protein amino acid dephosphorylation
Hs.160871 protein tyrosine phosphatase, receptor 
type, O
PTPRO 3.25 -2.31 4.20
Hs.43666 protein tyrosine phosphatase type IVA, 
member 3
PTP4A3 2.46 -2.83 4.66
Hs.497822 dual specificity phosphatase 10 DUSP10 2.14 -3.15 3.02
Other up-regulated gene expression
Hs.459265 interferon stimulated exonuclease gene 
20 kDa
ISG20 9.19 -4.57 8.10
Hs.118633 2'-5'-oligoadenylate synthetase-like OASL 8.00 -4.82 6.26
Hs.144873 BCL2/adenovirus E1B 19 kDa interacting 
protein 3
BNIP3 2.12 -2.35 4.19
Table 1: 65 genes upregulated by HIF-1alpha more than 2.0-fold in three pairwise comparisons (Continued)Journal of Experimental & Clinical Cancer Research 2009, 28:150 http://www.jeccr.com/content/28/1/150
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stained yellow for counting (Figure 5A). Analysis of the
apoptosis rate demonstrated that HIF-1alpha inhibited
apoptosis of NCI-H446 cells, but SOCS1 induced apopto-
sis (Figure 5B). Analysis of the co-transfection groups,
such as the Ad5-HIF-1alpha/siSOCS1 group and Ad5-
siHIF-1alpha/SOCS1 group, displayed an inter-antago-
nism between HIF-1alpha and SOCS1 in regulating apop-
tosis of NCI-H446 cells even though HIF-1alpha
upregulated the expression of SOCS1 at both the mRNA
and protein levels (Figure 5B).
Discussion
Tissue hypoxia is critical in the process of tumor forma-
tion. Activation of HIF-1 alpha, an important transcrip-
tion factor that is expressed in response to hypoxia, is a
common feature of tumors and is generally more pro-
nounced in aggressive solid tumors such as SCLC and can
even be an independent predictor of prognosis in certain
types of cancer [9,10]. To characterize the molecular
mechanisms involved in the carcinogenesis, progression
and prognosis of SCLC which are regulated by HIF-1
alpha and identify genes to be applied as novel diagnostic
markers or for development of gene targeted therapy, we
applied cDNA microarray profile analysis and integrated
the results of gene expression profiles of the hypoxia, HIF-
1 alpha and siHIF-1 alpha groups. In this way, we could
eliminate the effects on gene expression by others factors
involving the hypoxic microenvironment and stringently
screened out the genes regulated by HIF-1alpha. From the
results of three pairwise comparisons we found that both
upregulated and downregulated genes were all associated
with these categories: transport, growth factors/cytokines,
transcription and protein amino acid phosphorylation.
Angiogenesis is essential for progression, invasion and
metastasis of SCLC[11]. As a specific target of most tumors
VEGF is a target gene of HIF-1 alpha and plays a main role
in control of angiogenesis both in physiological and path-
ological situations, including tumor development and
progression. It is mitogenic and angiogenic for endothe-
lial cells, and it can also increase vascular permeability
[12]. Identical with previous study [13] our study also
found that VEGF-A was upregulated by HIF-1 alpha more
than 6-fold in SCLC. But besides VEGF-A, there are several
other genes associated with angiogenesis such as PDGFC,
PLA2G4A, HMOX1, HMGA2 were upregulated by HIF-1
alpha. These genes were not reported in others literatures
and therefore we think the upregulation of these genes
may be specific to the angiogenesis of SCLC when
responding to HIF-1 alpha or hypoxia.
Some genes had been reported to be found with differen-
tial expression in SCLC through microarray analysis.
Amplification and overexpression of the MYC family of
oncogenes such as MYC (c-Myc), MYCN (N-Myc) and
MYCL1 (L-Myc) occured in SCLCs [14] and was common
in chemo-refractory disease[15]. In our study not MYC
family but SLC family such as SLC6A2 and SLC9A2 were
upregulated by HIF-1 alpha. Some genes as TAF5L,
TFCP2L4, PHF20, LMO4, TCF20 and RFX2 that were
known to have transcription factor activities express
highly in SCLC[16] but the genes that were upregulated by
HIF-1 alpha are TRIM22, IRF9, MYOCD, ZNF277 and
CREM from our study. Previous study also reported that
the high expression of BAI3, D4S234E, DCX, DPYSL5 and
GKAP1 which were related to signal transduction were
Real-time PCR analysis of upregulated or downregulated  gene expression in response to HIF-1alpha (A) Aliquots of  the same RNA preparations used for microarray hybridiza- tion were analyzed by quantitative real-time PCR Figure 2
Real-time PCR analysis of upregulated or downregu-
lated gene expression in response to HIF-1alpha (A) 
Aliquots of the same RNA preparations used for 
microarray hybridization were analyzed by quantita-
tive real-time PCR. In three pairwise comparisons, the 
upregulation-folds of IGFBP5, IRS4, TNFAIP6, SOCS1, IL-6, 
VEGF-A mRNA expression were calculated. The mean and 
standard error are shown (p < 0.05). (B) Aliquots of the 
same RNA preparations used for microarray hybridization 
were analyzed by quantitative real-time PCR. In three pair-
wise comparisons, the downregulation-folds of IGFBP3, 
ZNF569, SOCS2, SIRPa and XRCC4 mRNA were calculated. 
The mean and standard error are shown (p < 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:150 http://www.jeccr.com/content/28/1/150
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found in SCLC [16,17]. In our study signal transduction
factor IRS4 and GPER1 were upregulated by HIF-1 alpha
more than 6.0-fold. As for IRS4 some researchers have
found that it plays an important role in proliferation/dif-
ferentiation of tumors and exerts its actions through ERK
and p70S6K activation in a ras/raf/MEK1/2 and PI3K/Akt
independent manner and in a PKC-dependent way [18].
The GPER1 gene (also known as GPR30) represents an
alternative estrogen-responsive receptor, which is highly
expressed in tumors where estrogen and progesterone
receptors are downregulated and in high-risk tumor
patients with lower survival rates[19]. GPER1 is also an
important mediator of some single transduction path-
ways contributing to promote proliferation, metastasis
and aggressive behaviors of tumors that are induced by
endogenous estrogens, including drugs like hydroxyta-
moxifen and atrazine or the environmental pollutant cad-
mium [20-22].
Table 2: 28 genes downregulated by HIF-1alpha more than 2.0-fold in three pairwise comparisons
UniGeneID Gene name Gene Symbol Fold change(ratio ≥ 2)
Ad5-HIF-1alpha/Ad5 Ad5-siHIF-1alpha/Ad5 Hypoxia
/normoxia
Transport
Hs.666728 Na+/H+ exchanger domain containing 1 NHEDC1 -27.86 9.86 -12.33
Hs.666367 potassium voltage-gated channel, Shal-related 
subfamily, member 3
KCND3 -16.00 6.13 -11.82
Hs.581021 signal-regulatory protein alpha SIRPa -4.93 3.10 -3.72
Hs.504317 solute carrier family 16, member 14 
(monocarboxylic acid transporter 14)
SLC16A14 -4.59 2.46 -4.30
Hs.118695 potassium voltage-gated channel, subfamily G, 
member 1
KCNG1 -2.13 2.35 -3.17
Hs.158748 solute carrier family 35, member F3 SLC35F3 -2.06 2.76 -2.55
Hs.443625 collagen, type III, alpha 1 COL3A1 -2.29 2.16 -3.78
Transcription
Hs.458406 undifferentiated embryonic cell
transcription factor 1
KCNG1 -36.76 12.17 -45.69
Hs.511848 zinc finger protein 569 ZNF569 -12.13 7.61 -15.33
Hs.412196 intraflagellar transport 57 homolog IFT57 -8.58 4.38 -7.36
Hs.533977 thioredoxin interacting protein TXNIP -5.28 3.10 -5.01
Hs.4779 GATA zinc finger domain containing 2B GATAD2B -3.48 2.31 -6.30
Hs.9521 zinc finger protein 92 ZNF92 -2.83 2.09 -3.19
Hs.490273 cAMP responsive element binding
protein3-like 2
CREB3L2 -2.07 2.00 -3.12
Hs.524248 zinc finger protein 362 ZNF362 -2.00 2.67 -4.78
Growth factors/cytokines
Hs.485572 suppressor of cytokine signaling 2 SOCS2 -6.06 3.06 -7.12
Hs.450230 insulin-like growth factor binding
protein 3
IGFBP3 -4.02 2.17 -5.73
Hs.8867 cysteine-rich, angiogenic inducer, 61 CYR61 -3.03 2.18 -3.77
Hs.289008 nuclear undecaprenyl pyrophosphate-
synthase 1 homolog
NUS1 -2.83 2.13 -4.01
Hs.699288 neural precursor cell expressed, 
developmentally down-regulated 9
NEDD9 -2.64 2.26 -2.57
Protein amino acid phosphorylation
Hs.370503 FYN binding protein (FYB-120/130) FYB -6.06 3.97 -4.71
Hs.460355 protein kinase C, beta 1 PRKCB1 -3.25 2.56 -4.30
Hs.390729 v-erb-a erythroblastic leukemia viral 
oncogene homolog 4
ERBB4 -2.46 2.11 -3.89
Hs.654491 receptor tyrosine kinase-like orphan 
receptor 1
ROR1 -2.47 2.32 -4.56
Hs.653377 insulin-like growth factor 1 receptor IGF1R -2.00 2.89 -3.11
Other down-regulated gene expression
Hs.606356 pleckstrin homology domain interacting 
protein
PHIP -17.15 4.76 -10.03
Hs.567359 X-ray repair complementing defective repair 
in Chinese hamster cells 4
XRCC4 -8.00 6.21 -5.69
Hs.502182 brain-derived neurotrophic factor BDNF -2.30 2.14 -2.18Journal of Experimental & Clinical Cancer Research 2009, 28:150 http://www.jeccr.com/content/28/1/150
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A novel finding different from previous study is that some
genes encoding inflammatory response cytokines were
upregulated. This maybe provides a broad molecular-bio-
logical basis for the inflammatory effect of SCLC. The
highest upregulation are TNFAIP6 and IL6. TNFAIP6 can
inhibit osteoblastic differentiation of human mesenchy-
mal stem cells [23]. From this, we might conclude that
this is one potential mechanism of SCLC-mediated osteo-
clasia through upregulation of TNFAIP6 gene expression
by HIF-1 alpha. High expression of IL6 also is associated
with malignant tumors and deep vein thrombosis disease
[24]. This helps to explain why a hypercoagulable state is
usually associated with SCLC and what causes the throm-
bosis. Another novel finding is that with the genes in the
same family HIF-1 alpha upregulates the expression of
SOCS1 but downregulates the expression of SOCS2,
upregulates the expression of IGFBP5 but downregulates
the expression of IGFBP3. Clinical research has shown
that SOCS2 is an independent predictor for good progno-
sis, negative lymph nodes and has increased expression in
less malignant tumors [25]. From this the downregulation
of SOCS2 by HIF-1 alpha maybe worsen the prognosis of
Western blot analysis of regulation of protein expression by HIF-1alpha in NCI-H446 cells Figure 3
Western blot analysis of regulation of protein expression by HIF-1alpha in NCI-H446 cells. According to different 
treatments, all the cells were divided into four groups: control group (the cells cultured under normoxic conditions of 20% 
O2), Ad5-HIF-1alpha transfection group, hypoxia group (the cells cultured under normoxic conditions of 1% O2) and Ad5-
siHIF-1alpha transfection group (after transfection, the cells were cultured under normoxic conditions of 1% O2). (A) West-
ern blot analysis for IGFBP5 protein expressed by the cells of four groups. (B) Western blot analysis for SOCS1 protein 
expressed by the cells of four groups. (C) Densitometric analysis of the IGFBP5 and SOCS1 bands compared to the corre-
sponding β-actin bands (*p < 0.05 expression of IGFBP5 or SOCS1 protein in Ad5-HIF-1alpha group vs. control group; ** p < 
0.05 expression of IGFBP5 or SOCS1 protein in hypoxia group vs. control group; *** p < 0.05 expression of IGFBP5 or SOCS1 
protein in Ad5-siHIF-1alpha group vs. control group). (D) Western blot analysis for IL-6 protein expressed by the cells of four 
groups. (E) Western blot analysis for STAT3 protein expressed by the cells of four groups. (F) Densitometric analysis of the 
IL-6 and STAT3 bands compared to the corresponding β-actin bands (*p < 0.05 expression of IL-6 or STAT3 protein in Ad5-
HIF-1alpha group vs. Ad5-siHIF-1alpha group group.)Journal of Experimental & Clinical Cancer Research 2009, 28:150 http://www.jeccr.com/content/28/1/150
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SCLC. Besides these increased IGFBP-5 mRNA levels have
been proved to be associated with a poor outcome for the
patients who have positive lymph nodes[26] and high cir-
culating concentrations of IGFBP-3 is associated with a
lower cancer risk from clinical trail[27]. Thus upregula-
tion of IGFBP5 and downregulation of IGFBP3 by
hypoxia or HIF-1 alpha cannot be considered as good pre-
dictors of prognosis. As for SOCS1 some scholars have
demonstrated that SOCS1 plays an important role in
degrading IFN resistance of neuroendocrine tumor cells
through negative regulation of Jak/STAT signaling path-
way[28]. Our study demonstrates that SOCS1 potentially
induces the apoptosis and suppresses the growth of NCI-
H446 cells and therefore we thought the upregulation of
SOCS1 may be a good predictor for the prognosis of
SCLC. As an upstream regulatory factor that plays a con-
trary effect on the apoptosis and growth of SCLC cells,
through which mechanism HIF-1 alpha upregulates the
expression of.SOCS1, is a new problem to investigate. Pre-
vious study had demonstrated that the activation of
STAT3 mediated by IL-6 could upregulate the expression
of SOCS1 at mRNA and protein level [29]. From our study
we can see that the expression of STAT3 and IL-6 are both
upregulated at protein level. So we can primarily conclude
that HIF-1 alpha can upregulate the expression of SOCS1
through mediation of STAT3 and IL-6. As for the signal
transduction pathway involving in this pocess we will
carry out some resrarch work in the future.
Taken together, our data provide novel insights into the
composition and function of differential gene expression
regulated by HIF-1alpha in SCLC NCI-H446 cells.
Improving the survival rate of patients with SCLC requires
a better understanding of the function of genes associated
with tumorigenesis and the subsequent development of
novel gene therapeutic strategies including gene targeted
therapy. Several categories of targeted genes have been
introduced into clinical trials of SCLC [30] such as matrix
metalloproteinase inhibitors, anti-angiogenic agents
receptor and tyrosine kinase inhibitors. From our study it
Effect of HIF-1alpha and SOCS1 on cell growth was measured by cell counting Figure 4
Effect of HIF-1alpha and SOCS1 on cell growth was measured by cell counting. (A) After transfection with Ad5-
SOCS1, the growth of cells was slowed but promoted after transfection with Ad5-siSOCS1(*p < 0.05 Ad5-siSOCS1 group vs. 
Ad5 group; **p < 0.01 Ad5-SOCS1 group vs. Ad5 group) (B) After transfection with Ad5- HIF-1alpha, the growth of cells was 
promoted but slowed after transfection with Ad5- siHIF-1alpha (*p < 0.01 Ad5-HIF-1alpha group vs. Ad5 group; **p < 0.01 
Ad5-si HIF-1alpha group vs. Ad5 group). (C) In the Ad5-HIF-1alpha group, the growth of cells was promoted after blockade of 
SOCS1 by Ad5-siSOCS1 (*p < 0.01 Ad5- HIF-1alpha/siSOCS1 group vs. Ad5-HIF-1alpha group). (D) In the Ad5-si HIF-1alpha 
group, the growth of cells was slowed after co-transfection with SOCS1 (*p < 0.05 Ad5-siHIF-1alpha/SOCS1 group vs. Ad5-
siHIF-1alpha group). (E) In the Ad5-HIF-1alpha group, the growth of cells was slowed from day 5 to day 8 as the growth curve 
moved right after co-transfection with SOCS1 (*p < 0.05 Ad5-HIF-1alpha group vs. Ad5-HIF-1alpha/SOCS1 group).Journal of Experimental & Clinical Cancer Research 2009, 28:150 http://www.jeccr.com/content/28/1/150
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seems that regardless of upregulation or downregulation
of these functional genes, the trend of the tumor is to dete-
riorate due to the abnormal expression of genes mediated
by HIF-1alpha. Our work aims to find more novel func-
tional genes whose expression is mediated by HIF-1alpha
to support the development of new therapeutic targets for
gene targeted therapy of SCLC.
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